Publications
2024
Correction: Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study.
Coombes, R. C., Angelou, C., Al-Khalili, Z., Hart, W., Francescatti, D., Wright, N., . . . Palmieri, C. (2024). Correction: Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study.. Breast cancer research and treatment, 206(1), 209. doi:10.1007/s10549-024-07276-z
Analysis of Breast Cancer Brain Metastases Reveals an Enrichment of Cyclin-Dependent Kinase 12 Structural Rearrangements in Human Epidermal Growth Factor Receptor 2-Positive Disease.
Bhogal, T., Giannoudis, A., Sokol, E., Ali, S., & Palmieri, C. (2024). Analysis of Breast Cancer Brain Metastases Reveals an Enrichment of Cyclin-Dependent Kinase 12 Structural Rearrangements in Human Epidermal Growth Factor Receptor 2-Positive Disease.. JCO precision oncology, 8, e2300639. doi:10.1200/po.23.00639
Corrigendum to "A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone": [ESMO Open 8 (2023) 102033].
Pearson, J., Khan, A., Bhogal, T., Wong, H., Law, A., Mills, S., . . . Palmieri, C. (2024). Corrigendum to "A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone": [ESMO Open 8 (2023) 102033].. ESMO open, 9(6), 103621. doi:10.1016/j.esmoop.2024.103621
Abstract PO3-04-06: A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone
Pearson, J., Khan, A., Bhogal, T., Wong, H., Law, A., Mills, S., . . . Palmieri, C. (2024). Abstract PO3-04-06: A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone. Cancer Research, 84(9_Supplement). doi:10.1158/1538-7445.sabcs23-po3-04-06
Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study.
Turtle, L., Elliot, S., Drake, T. M., Thorpe, M., Khoury, E. G., Greenhalf, W., . . . ISARIC4C Investigators. (2024). Changes in hospital mortality in patients with cancer during the COVID-19 pandemic (ISARIC-CCP-UK): a prospective, multicentre cohort study.. The Lancet. Oncology, 25(5), 636-648. doi:10.1016/s1470-2045(24)00107-4
A randomised controlled trial of Pre-Operative Oncotype DX testing in early-stage breast cancer (PRE-DX study) - Study protocol.
Northgraves, M., Cohen, J., Harvey, J., Huang, C., Palmieri, C., Pinder, S., . . . Cain, H. (2024). A randomised controlled trial of Pre-Operative Oncotype DX testing in early-stage breast cancer (PRE-DX study) - Study protocol.. PloS one, 19(3), e0300339. doi:10.1371/journal.pone.0300339
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.
Palmieri, C., Linden, H., Birrell, S. N., Wheelwright, S., Lim, E., Schwartzberg, L. S., . . . Overmoyer, B. (2024). Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.. The Lancet. Oncology, 25(3), 317-325. doi:10.1016/s1470-2045(24)00004-4
Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer.
Coakley, M., Villacampa, G., Sritharan, P., Swift, C., Dunne, K., Kilburn, L., . . . Turner, N. C. (2024). Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(4), 895-903. doi:10.1158/1078-0432.ccr-23-2326
The future of cancer care in the UK-time for a radical and sustainable National Cancer Plan.
Aggarwal, A., Choudhury, A., Fearnhead, N., Kearns, P., Kirby, A., Lawler, M., . . . Sullivan, R. (2024). The future of cancer care in the UK-time for a radical and sustainable National Cancer Plan.. The Lancet. Oncology, 25(1), e6-e17. doi:10.1016/s1470-2045(23)00511-9
2023
Christmas cards: are senders full of joy and good cheer?
Gallagher, S., Howard, S., McMahon, J., & Palmieri, C. (2023). Christmas cards: are senders full of joy and good cheer?. COGENT PSYCHOLOGY, 10(1). doi:10.1080/23311908.2022.2151727
A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone.
Pearson, J., Khan, A., Bhogal, T., Wong, H., Law, A., Mills, S., . . . Palmieri, C. (2023). A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone.. ESMO open, 8(6), 102033. doi:10.1016/j.esmoop.2023.102033
Expert UK consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: A modified Delphi panel.
Copson, E. R., Abraham, J. E., Braybrooke, J. P., Cameron, D., McIntosh, S. A., Michie, C. O., . . . Delphi panellists. (2023). Expert UK consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: A modified Delphi panel.. Breast (Edinburgh, Scotland), 72, 103582. doi:10.1016/j.breast.2023.103582
Blocking channels to metastasis: targeting sodium transport in breast cancer.
Brackenbury, W. J., & Palmieri, C. (2023). Blocking channels to metastasis: targeting sodium transport in breast cancer.. Breast cancer research : BCR, 25(1), 140. doi:10.1186/s13058-023-01741-1
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program
Palmieri, C., Musson, A., Harper-Wynne, C., Wheatley, D., Bertelli, G., Macpherson, I. R., . . . Chowdhury, R. (2023). A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program. BRITISH JOURNAL OF CANCER. doi:10.1038/s41416-023-02352-5
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (vol 14, 4444, 2023)
Coombes, R. C., Howell, S., Lord, S. R., Kenny, L., Mansi, J., Mitri, Z., . . . Krebs, M. G. (2023). Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (vol 14, 4444, 2023). NATURE COMMUNICATIONS, 14(1). doi:10.1038/s41467-023-40561-x
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Coombes, R. C., Howell, S., Lord, S. R., Kenny, L., Mansi, J., Mitri, Z., . . . Krebs, M. G. (2023). Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. NATURE COMMUNICATIONS, 14(1). doi:10.1038/s41467-023-40061-y
Living with metastatic breast cancer (LIMBER): experiences, quality of life, gaps in information, care and support of patients in the UK
Fallowfield, L., Starkings, R., Palmieri, C., Tait, A., Stephen, L., May, S., . . . Jenkins, V. (2023). Living with metastatic breast cancer (LIMBER): experiences, quality of life, gaps in information, care and support of patients in the UK. SUPPORTIVE CARE IN CANCER, 31(8). doi:10.1007/s00520-023-07928-8
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Houten, R., Fleeman, N., Mahon, J., Chaplin, M., Edwards, K., Beale, S., . . . Palmieri, C. (2023). Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN. doi:10.1007/s41669-023-00405-2
Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay
Danziger, N., Sokol, E. S., Graf, R. P., Hiemenz, M. C., Maule, J., Parimi, V., . . . Huang, R. S. P. (2023). Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay. ONCOLOGIST. doi:10.1093/oncolo/oyad025
Targetable alterations and genomic signatures within breast cancer brain metastases: Data from comprehensive genomic profiling of 761 breast cancer brain metastases
Giannoudis, A., Sokol, E., Ramkissoon, S., Bhogal, T., Ross, J., McGregor, K., . . . Palmieri, C. (2023). Targetable alterations and genomic signatures within breast cancer brain metastases: Data from comprehensive genomic profiling of 761 breast cancer brain metastases. In CANCER RESEARCH Vol. 83. doi:10.1158/1538-7445.SABCS22-P5-14-10
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer
Turner, N. C., Swift, C., Jenkins, B., Kilburn, L., Coakley, M., Beaney, M., . . . Bliss, J. M. (2023). Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. ANNALS OF ONCOLOGY, 34(2), 200-211. doi:10.1016/j.annonc.2022.11.005
Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study.
Turtle, L., Thorpe, M., Drake, T. M., Swets, M., Palmieri, C., Russell, C. D., . . . Docherty, A. B. (2023). Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study.. PLoS medicine, 20(1), e1004086. doi:10.1371/journal.pmed.1004086
Identification of targetable genomic profiling of breast cancer brain metastases identifies alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors
2022
Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression
Giannoudis, A., Vareslija, D., Sharma, V., Zakaria, R., Platt-Higgins, A., Rudland, P. S., . . . Palmieri, C. (2022). Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression. ESMO OPEN, 7(6). doi:10.1016/j.esmoop.2022.100636
Estimated Prevalence of Metastatic Breast Cancer in England, 2016-2021.
Palmieri, C., Owide, J., & Fryer, K. (2022). Estimated Prevalence of Metastatic Breast Cancer in England, 2016-2021.. JAMA network open, 5(12), e2248069. doi:10.1001/jamanetworkopen.2022.48069
Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.
Siggins, M. K., Davies, K., Fellows, R., Thwaites, R. S., Baillie, J. K., Semple, M. G., . . . ISARIC4C Investigators. (2022). Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.. Immunology. doi:10.1111/imm.13585
An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves
Wysocki, O., Zhou, C., Rogado, J., Huddar, P., Shotton, R., Tivey, A., . . . Co-Care, E. S. M. O. (2022). An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves. Cancers, 14(16). doi:10.3390/cancers14163931
UK survey measuring informational needs & QoL in women living with metastatic breast cancer (LIMBER)
Jenkins, V. A., Russ, S., Starkings, R., Tait, A., Stephen, L., May, S., . . . FallowField, L. J. (2022). UK survey measuring informational needs & QoL in women living with metastatic breast cancer (LIMBER). In ANNALS OF ONCOLOGY Vol. 33 (pp. S637). doi:10.1016/j.annonc.2022.07.258
Breast cancer patient characterisation and visualisation using deep learning and fisher information networks
Ortega-Martorell, S., Riley, P., Olier, I., Raidou, R. G., Casana-Eslava, R., Rea, M., . . . Palmieri, C. (2022). Breast cancer patient characterisation and visualisation using deep learning and fisher information networks. SCIENTIFIC REPORTS, 12(1). doi:10.1038/s41598-022-17894-6
Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study
Fatayer, H., O'Connell, R. L., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., . . . McIntosh, S. A. (2022). Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study. BRITISH JOURNAL OF SURGERY, 109(9), 800-803. doi:10.1093/bjs/znac131
A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo<SUP>™</SUP>) in breast cancer patients with BONe metastases: CARBON trial results
Winter, M., Coleman, R., Kendall, J., Palmieri, C., Twelves, C., Howell, S., . . . Brown, J. (2022). A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo<SUP>™</SUP>) in breast cancer patients with BONe metastases: CARBON trial results. JOURNAL OF BONE ONCOLOGY, 35. doi:10.1016/j.jbo.2022.100442
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
Hall, B. J., Bhojwani, A. A., Wong, H., Law, A., Flint, H., Ahmed, E., . . . Palmieri, C. (2022). Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience. BREAST JOURNAL, 2022. doi:10.1155/2022/7146172
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force
Razis, E., Escudero, M. J., Palmieri, C., Mueller, V., Bartsch, R., Rossi, G., . . . Linderholm, B. (2022). Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. ESMO OPEN, 7(3). doi:10.1016/j.esmoop.2022.100483
Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review
Bhogal, T., Cameron, D., & Palmieri, C. (2022). Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review. BREAST, 63, 85-100. doi:10.1016/j.breast.2022.03.013
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.
Lee, R. J., Wysocki, O., Zhou, C., Shotton, R., Tivey, A., Lever, L., . . . Armstrong, A. C. (2022). Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.. JCO clinical cancer informatics, 6, e2100177. doi:10.1200/cci.21.00177
Rivaroxaban compared to no treatment in early breast cancer patients (the TIP Trial): initial findings for a phase II preoperative window-of-opportunity randomised controlled trial
Kirwan, C. C., Castle, J., Pritchard, S. A., Bundred, N. J., Thachill, J., Harvey, J. R., . . . Holcombe, C. (2022). Rivaroxaban compared to no treatment in early breast cancer patients (the TIP Trial): initial findings for a phase II preoperative window-of-opportunity randomised controlled trial. In THROMBOSIS RESEARCH Vol. 213 (pp. S5-S6). Retrieved from https://www.webofscience.com/
Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer A Systematic Review and Meta-analysis
Khoury, E., Nevitt, S., Madsen, W. R., Turtle, L., Davies, G., & Palmieri, C. (2022). Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer A Systematic Review and Meta-analysis. JAMA NETWORK OPEN, 5(5). doi:10.1001/jamanetworkopen.2022.10880
The importance of ARG2 expression in the immune-depleted microenvironment of primary breast cancer and brain metastasis
Giannoudis, A., Vareslija, D., Sharma, V., Zakaria, R., Platt-Higgins, A., Rudland, P., . . . Palmieri, C. (2022). The importance of ARG2 expression in the immune-depleted microenvironment of primary breast cancer and brain metastasis. In ANNALS OF ONCOLOGY Vol. 33 (pp. S132). doi:10.1016/j.annonc.2022.03.035
Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study
Narhi, F., Moonesinghe, S. R., Shenkin, S. D., Drake, T. M., Mulholland, R. H., Donegan, C., . . . Docherty, A. B. (2022). Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. LANCET DIGITAL HEALTH, 4(4). Retrieved from https://www.webofscience.com/
Comprehensive analysis of the gene rearrangements within 822 breast cancer brain metastases reveals an enrichment of cyclin dependent kinase 12 rearrangements in HER2-positive brain metastases
Bhogal, T., Sokol, E., Ramkissoon, S., Giannoudis, A., McGregor, K., Clark, A., . . . Palmieri, C. (2022). Comprehensive analysis of the gene rearrangements within 822 breast cancer brain metastases reveals an enrichment of cyclin dependent kinase 12 rearrangements in HER2-positive brain metastases. In CANCER RESEARCH Vol. 82. doi:10.1158/1538-7445.SABCS21-P5-07-04
Comprehensive assessment of the genomic landscape of breast cancer brain metastases reveals targetable alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors
Giannoudis, A., Sokol, E., Ramkissoon, S. H., Bhogal, T., McGregor, K., Clark, A., . . . Palmieri, C. (2022). Comprehensive assessment of the genomic landscape of breast cancer brain metastases reveals targetable alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors. In CANCER RESEARCH Vol. 82. doi:10.1158/1538-7445.SABCS21-PD4-09
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., . . . Screaton, G. R. (2022). SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.. Cell, 185(3), 467-484.e15. doi:10.1016/j.cell.2021.12.046
Expert Discussion: SABCS 2021
Bartsch, R., Kolberg-Liedtke, C., Jerusalem, G., Palmieri, C., & Janni, W. (2022). Expert Discussion: SABCS 2021. BREAST CARE, 17(1), 101-106. doi:10.1159/000521762
2021
Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival
Giannoudis, A., Sartori, A., Eastoe, L., Zakaria, R., Charlton, C., Hickson, N., . . . Palmieri, C. (2021). Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival. BREAST CANCER RESEARCH AND TREATMENT, 190(2), 241-253. doi:10.1007/s10549-021-06364-8
A prenylated dsRNA sensor protects against severe COVID-19
Wickenhagen, A., Sugrue, E., Lytras, S., Kuchi, S., Noerenberg, M., Turnbull, M. L., . . . Wilson, S. J. (2021). A prenylated dsRNA sensor protects against severe COVID-19. SCIENCE, 374(6567). doi:10.1126/science.abj3624
The Role of the Immune Response in Brain Metastases: Novel Imaging Biomarkers for Immunotherapy
Zakaria, R., Radon, M., Mills, S., Mitchell, D., Palmieri, C., Chung, C., & Jenkinson, M. D. (2021). The Role of the Immune Response in Brain Metastases: Novel Imaging Biomarkers for Immunotherapy. FRONTIERS IN ONCOLOGY, 11. doi:10.3389/fonc.2021.711405
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases
Huang, R. S. P., Haberberger, J., McGregor, K., Mata, D. A., Decker, B., Hiemenz, M. C., . . . Ramkissoon, S. H. (2021). Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. ONCOLOGIST, 26(10), 835-844. doi:10.1002/onco.13855
A global survey of the management of carcinomatous meningitis (CM) in breast cancer patients
Razis, E., Thulin, A. G., Bartsch, R., Escudero, M. J., Linderholm, B., Fumagali, D., . . . Witzel, I. (2021). A global survey of the management of carcinomatous meningitis (CM) in breast cancer patients. In ANNALS OF ONCOLOGY Vol. 32 (pp. S500). doi:10.1016/j.annonc.2021.08.594
A real-world data analysis: The first United Kingdom experience of cyclin-dependent kinase 4/6 inhibitor in advanced breast cancer in the National Health Service within an access program
Palmieri, C., Musson, A., Harper-Wynne, C., Wheatley, D., Bertelli, G., MacPherson, I., . . . Chowdhury, R. (2021). A real-world data analysis: The first United Kingdom experience of cyclin-dependent kinase 4/6 inhibitor in advanced breast cancer in the National Health Service within an access program. In ANNALS OF ONCOLOGY Vol. 32 (pp. S464). doi:10.1016/j.annonc.2021.08.523
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer The REACT Randomized Clinical Trial
Coombes, R. C., Tovey, H., Kilburn, L., Mansi, J., Palmieri, C., Bartlett, J., . . . Bliss, J. M. (2021). Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer The REACT Randomized Clinical Trial. JAMA ONCOLOGY, 7(9), 1291-1301. doi:10.1001/jamaoncol.2021.2193
LBA60 Prospective data of >20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK
Palmieri, C., Turtle, L., Drake, T., Harrison, E., Docherty, A., Greenhalf, B., . . . Semple, M. M. G. (2021). LBA60 Prospective data of >20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK. In Annals of oncology : official journal of the European Society for Medical Oncology Vol. 32 (pp. S1337).
Prospective data of >20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK
Palmieri, C., Turtle, L., Drake, T., Harrison, E., Docherty, A., Greenhalf, B., . . . Semple, M. M. G. (2021). Prospective data of >20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK. In ANNALS OF ONCOLOGY Vol. 32 (pp. S1337). doi:10.1016/j.annonc.2021.08.2141
Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR plus BC)
Howell, S. J., Krebs, M. G., Lord, S., Kenny, L., Bahl, A., Clack, G., . . . Coombes, R. C. (2021). Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR plus BC). In ANNALS OF ONCOLOGY Vol. 32 (pp. S477-S478). doi:10.1016/j.annonc.2021.08.548
Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study
Drake, T. M., Riad, A. M., Fairfield, C. J., Egan, C., Knight, S. R., Pius, R., . . . Semple, M. G. (2021). Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. LANCET, 398(10296), 223-237. Retrieved from https://www.webofscience.com/
A review of the evidence base for utilizing Child-Pugh criteria for guiding dosing of anticancer drugs in patients wan cancer and liver impairment
Palmieri, C., & Macpherson, I. R. (2021). A review of the evidence base for utilizing Child-Pugh criteria for guiding dosing of anticancer drugs in patients wan cancer and liver impairment. ESMO OPEN, 6(3). doi:10.1016/j.esmoop.2021.100162
Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR plus /ER plus breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study
Palmieri, C., Linden, H., Birrell, S., Lim, E., Schwartzberg, L. S., Rugo, H. S., . . . Overmoyer, B. (2021). Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR plus /ER plus breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study. In ANNALS OF ONCOLOGY Vol. 32 (pp. S66). doi:10.1016/j.annonc.2021.03.114
Genomic Profiling Using The UltraSEEK Panel Identifies Discordancy Between Paired Primary And Breast Cancer Brain Metastases And An Association With Brain Metastasis-Free Survival
Erratum to "Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome"
Lee, R. J., Wysocki, O., Bhogal, T., Shotton, R., Tivey, A., Angelakas, A., . . . Armstrong, A. C. (2021). Erratum to "Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome". ESMO OPEN, 6(2). doi:10.1016/j.esmoop.2021.100056
Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305
Macpherson, I. R., He, Y., & Palmieri, C. (2021). Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305. BREAST CANCER RESEARCH, 23(1). doi:10.1186/s13058-021-01407-w
What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol.
Sigfrid, L., Cevik, M., Jesudason, E., Lim, W. S., Rello, J., Amuasi, J., . . . Scott, J. T. (2021). What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol.. BMJ Open, 11(3), e043887. doi:10.1136/bmjopen-2020-043887
Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe
Vrdoljak, E., Gligorov, J., Wierinck, L., Conte, P., De Greve, J., Meunier, F., . . . Cardoso, F. (2021). Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe. BREAST, 55, 79-90. doi:10.1016/j.breast.2020.12.005
Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome
Lee, R. J., Wysocki, O., Bhogal, T., Shotton, R., Tivey, A., Angelakas, A., . . . Armstrong, A. C. (2021). Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome. ESMO OPEN, 6(1). doi:10.1016/j.esmoop.2020.100005
The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer
Hickey, T. E., Selth, L. A., Chia, K. M., Laven-Law, G., Milioli, H. H., Roden, D., . . . Tilley, W. D. (2021). The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. NATURE MEDICINE, 27(2), 310-+. doi:10.1038/s41591-020-01168-7
Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.
Bhogal, T., Khan, U. T., Lee, R., Stockdale, A., Hesford, C., Potti-Dhananjaya, V., . . . Palmieri, C. (2021). Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.. Leukemia & lymphoma, 1-16. doi:10.1080/10428194.2021.1876865
The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making
Whitehead, I., Irwin, G. W., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., . . . McIntosh, S. A. (2021). The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making. BMC CANCER, 21(1). doi:10.1186/s12885-020-07757-6
1'-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells.
Pradubyat, N., Giannoudis, A., Elmetwali, T., Mahalapbutr, P., Palmieri, C., Mitrpant, C., & Ketchart, W. (2021). 1'-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells.. Planta Medica. doi:10.1055/a-1307-3997
A NATIONAL STUDY OF THE EXPERIENCES, INFORMATION NEEDS AND ATTITUDES TO CLINICAL RESEARCH OF PATIENTS LIVING WITH SECONDARY BREAST CANCER IN THE UK
Stephen, L., Dunn, J., Palmieri, C., & Balmer, C. (2021). A NATIONAL STUDY OF THE EXPERIENCES, INFORMATION NEEDS AND ATTITUDES TO CLINICAL RESEARCH OF PATIENTS LIVING WITH SECONDARY BREAST CANCER IN THE UK. In BREAST Vol. 59 (pp. S42-S43). Retrieved from https://www.webofscience.com/
A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON) - Safety and preliminary efficacy findings
Winter, M., Kendall, J., Brown, S., Rathbone, E., Wilson, C., Howell, S., . . . Brown, J. (2021). A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON) - Safety and preliminary efficacy findings. In CANCER RESEARCH Vol. 81. Retrieved from https://www.webofscience.com/
BMSCOPE: A SYSTEMATIC MAPPING REVIEW OF BRAIN/LEPTOMENINGEAL METASTASIS CLINICAL STUDIES FROM 2010 TO 2020
Cheng, V. W. T., Heywood, R., Zakaria, R., Burger, R., Fitzpatrick, A., Zucker, K., . . . Jenkinson, M. D. (2021). BMSCOPE: A SYSTEMATIC MAPPING REVIEW OF BRAIN/LEPTOMENINGEAL METASTASIS CLINICAL STUDIES FROM 2010 TO 2020. In NEURO-ONCOLOGY Vol. 23 (pp. 51). Retrieved from https://www.webofscience.com/
Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease
Page, K., Martinson, L. J., Fernandez-Garcia, D., Hills, A., Gleason, K. L. T., Gray, M. C., . . . Shaw, J. A. (2021). Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. JCO PRECISION ONCOLOGY, 5, 1768-1776. doi:10.1200/PO.20.00522
Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER plus /AR plus breast cancer - final results from an international Phase 2 randomized study
Palmieri, C., Linden, H., Birrell, S., Lim, E., Schwartzberg, L. S., Rugo, H. S., . . . Overmoyer, B. (2021). Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER plus /AR plus breast cancer - final results from an international Phase 2 randomized study. In CANCER RESEARCH Vol. 81. Retrieved from https://www.webofscience.com/
The genomic landscape of breast cancer brain metastases: a systematic review.
Morgan, A. J., Giannoudis, A., & Palmieri, C. (2021). The genomic landscape of breast cancer brain metastases: a systematic review.. The Lancet. Oncology, 22(1), e7-e17. doi:10.1016/S1470-2045(20)30556-8
2020
Establishment of CORONET; COVID-19 Risk in Oncology Evaluation Tool to identify cancer patients at low versus high risk of severe complications of COVID-19 infection upon presentation to hospital
Lee, R. J., Zhou, C., Wysocki, O., Shotton, R., Tivey, A., Lever, L., . . . Armstrong, A. C. (2020). Establishment of CORONET; COVID-19 Risk in Oncology Evaluation Tool to identify cancer patients at low versus high risk of severe complications of COVID-19 infection upon presentation to hospital. doi:10.1101/2020.11.30.20239095
Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer
Giannoudis, A., Malki, M. I., Rudraraju, B., Mohhamed, H., Menon, S., Liloglou, T., . . . Palmieri, C. (2020). Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer. Breast Cancer Research, 22(1). doi:10.1186/s13058-020-01359-7
Trastuzumab Beyond Progression in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: UK Practice now and in the Future
Robinson, T., Palmieri, C., & Braybrooke, J. P. (2020). Trastuzumab Beyond Progression in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: UK Practice now and in the Future. CLINICAL ONCOLOGY, 32(10), 636-638. doi:10.1016/j.clon.2020.04.008
Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium
Palmieri, C., Turtle, L., Docherty, A., Harrison, E., Drake, T., Greenhalf, B., . . . Semple, M. G. (2020). Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium. In ANNALS OF ONCOLOGY Vol. 31 (pp. S992). doi:10.1016/j.annonc.2020.08.1735
What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study
Sigfrid, L., Cevik, M., Jesudason, E., Lim, W. S., Rello, J., Amuasi, J. H., . . . Scott, J. (2020). What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study. doi:10.1101/2020.08.26.20180950
Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial
Castle, J., Blower, E., Bundred, N. J., Harvey, J. R., Thachil, J., Marshall, A., . . . Kirwan, C. C. (2020). Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial. TRIALS, 21(1). doi:10.1186/s13063-020-04675-7
Cancer datasets and the SARS-CoV-2 pandemic: establishing principles for collaboration.
Palmieri, C., Palmer, D., Openshaw, P. J., Baille, J. K., Semple, M. G., & Turtle, L. (2020). Cancer datasets and the SARS-CoV-2 pandemic: establishing principles for collaboration.. ESMO Open, 5(3). doi:10.1136/esmoopen-2020-000825
A breast cancer trainees research collaborative group prospective study of treatment and outcomes related to central nervous system disease secondary to breast cancer in the United Kingdom
Cheng, V. W. T., McKenzie, H. S., Kwan, A., Konstantis, A., Ma, R., Teo, P. J., . . . Palmieri, C. (2020). A breast cancer trainees research collaborative group prospective study of treatment and outcomes related to central nervous system disease secondary to breast cancer in the United Kingdom. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-OT3-10-02
A systematic review of the receptor status and genomic landscape of breast cancer brain metastases
Morgan, A. J., Giannoudis, A., & Palmieri, C. (2020). A systematic review of the receptor status and genomic landscape of breast cancer brain metastases. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-P4-05-22
National utilisation of neoadjuvant systemic therapy and impact on surgical treatment - A prospective multi-centre cohort study
McIntosh, S. A., Irwin, G. W., Bannon, F., Coles, C., Copson, E., Cutress, R., . . . Potter, S. (2020). National utilisation of neoadjuvant systemic therapy and impact on surgical treatment - A prospective multi-centre cohort study. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-P2-16-04
The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer
Lim, E., Hickey, T. A., Selth, L. A., Chia, K. M., Milioli, H. H., Roden, D., . . . Tilley, W. D. (2020). The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-GS2-03
The regulatory role of activating transcription factor-2 (ATF2) in modulating tamoxifen resistance in estrogen-receptor positive breast cancer
Giannoudis, A., Malki, M. I., Mohammed, H., Rudraraju, B., Menon, S., Ali, S., . . . Palmieri, C. (2020). The regulatory role of activating transcription factor-2 (ATF2) in modulating tamoxifen resistance in estrogen-receptor positive breast cancer. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-P6-04-18
UltraSEEK breast cancer panel for low frequency mutation detection in breast cancer brain metastasis
Giannoudis, A., Eastoe, L., Charlton, C., Hickson, N., Zakaria, R., Platt-Higgins, A., . . . Palmieri, C. (2020). UltraSEEK breast cancer panel for low frequency mutation detection in breast cancer brain metastasis. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-P4-09-07
CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial
Coleman, R., Brown, J., Rathbone, E., Flanagan, L., Reid, A., Kendall, J., . . . Brown, S. (2020). CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial. TRIALS, 21(1). doi:10.1186/s13063-019-3643-6
Surgical outcomes following neoadjuvant chemotherapy: a UK national prospective multi-centre cohort study
McIntosh, S. A., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., Dave, R. V., . . . Potter, S. (2020). Surgical outcomes following neoadjuvant chemotherapy: a UK national prospective multi-centre cohort study. In BREAST CANCER RESEARCH AND TREATMENT Vol. 180 (pp. 528-529). Retrieved from https://www.webofscience.com/
The Breast Cancer Trainees Research Collaborative Group: A New Multidisciplinary Network to Facilitate Breast Cancer Research
Cheng, V. W. T., Heetun, A., Robinson, T., Coles, C. E., Palmieri, C., Rea, D., & Copson, E. R. (2020). The Breast Cancer Trainees Research Collaborative Group: A New Multidisciplinary Network to Facilitate Breast Cancer Research. CLINICAL ONCOLOGY, 32(1), E16-E18. doi:10.1016/j.clon.2019.06.019
The breast cancer trainees research collaborative group
Copson, E., Coles, C., Kirwan, C., McIntosh, S., Palmieri, C., & Rea, D. (2020). The breast cancer trainees research collaborative group. In BREAST CANCER RESEARCH AND TREATMENT Vol. 180 (pp. 595). Retrieved from https://www.webofscience.com/
The landscape of systemic regimens used routinely in the neoadjuvant setting in the UK: the NEST national prospective multi-centre cohort study
Copson, E. R., Bannon, F., Coles, C. E., Cutress, R. I., Dave, R. V., Gardiner, M., . . . McIntosh, S. A. (2020). The landscape of systemic regimens used routinely in the neoadjuvant setting in the UK: the NEST national prospective multi-centre cohort study. In BREAST CANCER RESEARCH AND TREATMENT Vol. 180 (pp. 561-562). Retrieved from https://www.webofscience.com/
Window of opportunity treatment in breast cancer
Chen, J., Easwaralingam, N., Warrier, S., Ong, A., Carson, E. -K., Mak, C., . . . Segara, D. (2020). Window of opportunity treatment in breast cancer. ANZ JOURNAL OF SURGERY, 90(1-2), 34-40. doi:10.1111/ans.15487
2019
A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival
Giannoudis, A., Clarke, K., Zakaria, R., Vareslija, D., Farahani, M., Rainbow, L., . . . Palmieri, C. (2019). A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival. SCIENTIFIC REPORTS, 9. doi:10.1038/s41598-019-55084-z
Prospective Observational Study in Patients with Metastatic Breast Cancer Involving the Central Nervous System (PRIMROSE)
Fitzpatrick, A., Konstantis, A., & Palmieri, C. (2019). Prospective Observational Study in Patients with Metastatic Breast Cancer Involving the Central Nervous System (PRIMROSE). In CLINICAL ONCOLOGY Vol. 31 (pp. E108). doi:10.1016/j.clon.2019.03.016
Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution
Palmieri, C., & Macpherson, I. (2019). Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution. LANCET ONCOLOGY, 20(6), E289. doi:10.1016/S1470-2045(19)30296-7
Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells
Ruenraroengsak, P., Kiryushko, D., Theodorou, I. G., Klosowski, M. M., Taylor, E. R., Niriella, T., . . . Porter, A. E. (2019). Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells. NANOSCALE, 11(27), 12858-12870. doi:10.1039/c9nr01277j
Real-world data regarding the efficacy of neoadjuvant carboplatin-paclitaxel followed by dose-dense adriamycin-cyclophosphamide for triple-negative early breast cancer.
Bhojwani, A. A., Flint, H., Hall, B. J., Wong, H., Innes, H., Cliff, J., . . . Palmieri, C. (2019). Real-world data regarding the efficacy of neoadjuvant carboplatin-paclitaxel followed by dose-dense adriamycin-cyclophosphamide for triple-negative early breast cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. doi:10.1200/JCO.2019.37.15_suppl.e12559
Real-world evidence regarding the efficacy and toxicity of neoadjuvant trastuzumab and pertuzumab in the management of HER2-positive early-breast cancer.
Hall, B. J., Bhojwani, A. A., Innes, H., Ahmed, E., Cliff, J., Malik, Z., . . . Palmieri, C. (2019). Real-world evidence regarding the efficacy and toxicity of neoadjuvant trastuzumab and pertuzumab in the management of HER2-positive early-breast cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. doi:10.1200/JCO.2019.37.15_suppl.e12108
Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES
Szijgyarto, Z., Flach, K. D., Opdam, M., Palmieri, C., Linn, S. C., Wesseling, J., . . . Coombes, R. C. (2019). Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES. BREAST CANCER RESEARCH AND TREATMENT, 175(1), 149-163. doi:10.1007/s10549-018-05110-x
The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool
Olsson-Brown, A., Piskilidis, P., O'Hagan, J., Thorp, N., Robson, P., Innes, H., . . . Palmieri, C. (2019). The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool. BREAST, 44, 94-100. doi:10.1016/j.breast.2019.01.005
Identification of microRNAs differentially expressed in brain metastasis secondary to breast cancer
Giannoudis, A., Clarke, K., Zakaria, R., Vareslija, D., Farahani, M., Rainbow, L., . . . Palmieri, C. (2019). Identification of microRNAs differentially expressed in brain metastasis secondary to breast cancer. In CANCER RESEARCH Vol. 79. doi:10.1158/1538-7445.SABCS18-P6-05-02
Profiling the early haematological dynamics and treatment modifications with palbociclib when used as first line treatment for ER-positive, HER2-negative metastatic breast cancer
Bhojwani, A., Flint, H., Hall, B., Wong, H., Innes, H., Cliff, J., . . . Palmieri, C. (2019). Profiling the early haematological dynamics and treatment modifications with palbociclib when used as first line treatment for ER-positive, HER2-negative metastatic breast cancer. In CANCER RESEARCH Vol. 79. doi:10.1158/1538-7445.SABCS18-P6-18-32
Real world experience of the medical and surgical management of HER2 positive early breast cancer treated with neoadjuvant trastuzumab and pertuzumab via the NHS England cancer drug fund
Hall, B., Bhojwani, A., Innes, H., Ahmed, E., Cliff, J., Malik, Z., . . . Palmieri, C. (2019). Real world experience of the medical and surgical management of HER2 positive early breast cancer treated with neoadjuvant trastuzumab and pertuzumab via the NHS England cancer drug fund. In CANCER RESEARCH Vol. 79. doi:10.1158/1538-7445.SABCS18-P6-17-27
Radiant-BC Platform Trial: Development of an efficient multiarm multi-stage early phase trial of radiosurgery with immunotherapy and systemic therapies in breast cancer patients with brain metastases using a flexible Bayesian framework
Yap, C., Kong, A., Slade, D., Jackson, R., Savage, J., Sanghera, P., . . . Palmieri, C. (2019). Radiant-BC Platform Trial: Development of an efficient multiarm multi-stage early phase trial of radiosurgery with immunotherapy and systemic therapies in breast cancer patients with brain metastases using a flexible Bayesian framework. In TRIALS Vol. 20. Retrieved from https://www.webofscience.com/
The NeST (neoadjuvant systemic therapy in breast cancer) study - Protocol for a prospective multi-centre cohort study to assess the current utilization and short-term outcomes of neoadjuvant systemic therapies in breast cancer
Irwin, G. W., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., Dave, R. V., . . . McIntosh, S. A. (2019). The NeST (neoadjuvant systemic therapy in breast cancer) study - Protocol for a prospective multi-centre cohort study to assess the current utilization and short-term outcomes of neoadjuvant systemic therapies in breast cancer. INTERNATIONAL JOURNAL OF SURGERY PROTOCOLS, 18, 5-11. doi:10.1016/j.isjp.2019.10.002
2018
Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer
Patten, D. K., Corleone, G., Gyorffy, B., Perone, Y., Slaven, N., Barozzi, I., . . . Magnani, L. (2018). Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. NATURE MEDICINE, 24(9), 1469-+. doi:10.1038/s41591-018-0091-x
The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome
Ricciardelli, C., Bianco-Miotto, T., Jindal, S., Butler, L. M., Leung, S., McNeil, C. M., . . . Tilley, W. D. (2018). The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. Clinical Cancer Research, 24(10), 2328-2341. doi:10.1158/1078-0432.CCR-17-1199
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES
Cheang, M. C. U., Bliss, J. M., Viale, G., Speirs, V., Palmieri, C., Shaaban, A., . . . Coombes, R. C. (2018). Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. BREAST CANCER RESEARCH AND TREATMENT, 168(1), 169-178. doi:10.1007/s10549-017-4543-7
A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn celecoxib trial)
Coombes, R. C., Tovey, H., Kilburn, L., Mansi, J., Palmieri, C., Bartlett, J., . . . Bliss, J. (2018). A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn celecoxib trial). In CANCER RESEARCH Vol. 78. Retrieved from https://www.webofscience.com/
A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA)
Loibl, S., Barinoff, J., Seiler, S., Decker, T., Denkert, C., Hardy-Bessard, A. -C., . . . Thill, M. (2018). A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA). In CANCER RESEARCH Vol. 78. Retrieved from https://www.webofscience.com/
IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients (vol 165, pg 343, 2017)
Palmieri, C., Stein, R. C., Liu, X., Hudson, E., Nicholas, H., Sasano, H., . . . Coombes, R. C. (2018). IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients (vol 165, pg 343, 2017). BREAST CANCER RESEARCH AND TREATMENT, 167(1), 407. doi:10.1007/s10549-017-4539-3
2017
IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer
Palmieri, C., Szydlo, R., Miller, M., Barker, L., Patel, N. H., Sasano, H., . . . Kenny, L. M. (2017). IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 166(2), 527-539. doi:10.1007/s10549-017-4427-x
Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer (vol 5, 30, 2015)
Saleem, A., Searle, G. E., Kenny, L. M., Huiban, M., Kozlowski, K., Waldman, A. D., . . . Coombes, R. C. (2017). Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer (vol 5, 30, 2015). EJNMMI RESEARCH, 7. doi:10.1186/s13550-017-0325-9
Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer (vol 5, 30, 2015)
Saleem, A., Searle, G. E., Kenny, L. M., Huiban, M., Kozlowski, K., Waldman, A. D., . . . Coombes, R. C. (2017). Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer (vol 5, 30, 2015). EJNMMI RESEARCH, 7. doi:10.1186/s13550-017-0323-y
IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients
Palmieri, C., Stein, R. C., Liu, X., Hudson, E., Nicholas, H., Sasano, H., . . . Coombes, R. C. (2017). IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. BREAST CANCER RESEARCH AND TREATMENT, 165(2), 343-353. doi:10.1007/s10549-017-4328-z
First stage of an on-going phase 2, open label, international, randomized, parallel design study investigating efficacy plus safety of GTx-024 for advanced ER plus /AR plus breast cancer (BC)
Overmoyer, B., Rugo, H. S., Johnston, S., O'Shaughnessy, J. A., Palmieri, C., Schwartzberg, L. S., . . . Johnston, M. A. (2017). First stage of an on-going phase 2, open label, international, randomized, parallel design study investigating efficacy plus safety of GTx-024 for advanced ER plus /AR plus breast cancer (BC). In ANNALS OF ONCOLOGY Vol. 28. Retrieved from https://www.webofscience.com/
Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases
Giannoudis, A., Zakaria, R., Platt-Higgins, A., Syed, K. A. R., Ashton, K., Dawson, T., . . . Palmieri, C. (2017). Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases. In CANCER RESEARCH Vol. 77. doi:10.1158/1538-7445.SABCS16-P2-03-04
2016
Pushing estrogen receptor around in breast cancer
Lim, E., Tarulli, G., Portman, N., Hickey, T. E., Tilley, W. D., & Palmieri, C. (2016). Pushing estrogen receptor around in breast cancer. ENDOCRINE-RELATED CANCER, 23(12), T227-T241. doi:10.1530/ERC-16-0427
Renewed interest in the progesterone receptor in breast cancer
Lim, E., Palmieri, C., & Tilley, W. D. (2016). Renewed interest in the progesterone receptor in breast cancer. BRITISH JOURNAL OF CANCER, 115(8), 909-911. doi:10.1038/bjc.2016.303
Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer
Coombes, R. C., Kilburn, L. S., Tubiana-Mathieu, N., Olmos, T., Van Bochove, A., Perez-Lopez, F. R., . . . Bliss, J. M. (2016). Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer. EUROPEAN JOURNAL OF CANCER, 60, 146-153. doi:10.1016/j.ejca.2016.03.001
A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IRIS) - Trial Results.
Palmieri, C., Stein, R. C., Liu, X., Hudson, E., Reed, S., Nicholas, H., . . . Coombes, C. (2016). A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IRIS) - Trial Results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.549
The effects of the first in class steroid sulfatase inhibitor Irosustat on FLT uptake and Ki67 in estrogen receptor positive early breast cancer: Results of the perioperative IPET study.
Palmieri, C., Szydlo, R., Miller, M., Woodley-Barker, L., Patel, N., Berwick, T., . . . Kenny, L. M. (2016). The effects of the first in class steroid sulfatase inhibitor Irosustat on FLT uptake and Ki67 in estrogen receptor positive early breast cancer: Results of the perioperative IPET study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.e23140
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
Palmieri, C., Macpherson, I. R. J., Yan, K., Ades, F., Riddle, P., Ahmed, R., . . . Howell, S. J. (2016). Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. ONCOTARGET, 7(11), 13209-13220. doi:10.18632/oncotarget.4801
A phase 2 open label, multi-center, multinational study investigating the efficacy and safety of GTx-024 on advanced, androgen receptor-positive triple negative breast cancer (AR plus TNBC)
Rugo, H., Overmoyer, B., Schwartzberg, L., Palmieri, C., Taylor, R., Hancock, M., . . . Johnston, M. A. (2016). A phase 2 open label, multi-center, multinational study investigating the efficacy and safety of GTx-024 on advanced, androgen receptor-positive triple negative breast cancer (AR plus TNBC). In CANCER RESEARCH Vol. 76. doi:10.1158/1538-7445.SABCS15-OT2-01-07
A study of c-Jun N -terminal kinase (JNK) and c-Jun as biomarkers in early breast cancer
Palmieri, C., Rudraraju, B., Giannoudis, A., Moore, D., Shaw, J., Chan, S., . . . Abdel-Fatah, T. M. A. (2016). A study of c-Jun N -terminal kinase (JNK) and c-Jun as biomarkers in early breast cancer. In CANCER RESEARCH Vol. 76. doi:10.1158/1538-7445.SABCS15-P5-08-17
Knowledge of oncotype Dx recurrence score increases confidence and concordance in adjuvant decisions of UK oncologists
Kiernan, T., Olsson-Brown, A. C., Innes, H., Holcombe, C., Thorp, N., O'Hagan, J., . . . O'Reilly, S. (2016). Knowledge of oncotype Dx recurrence score increases confidence and concordance in adjuvant decisions of UK oncologists. In CANCER RESEARCH Vol. 76. doi:10.1158/1538-7445.SABCS15-P5-15-07
Phase 2 open label, multinational, randomized, parallel design study investigating the efficacy and safety of GTx-024 on metastatic (MET) or locally advanced (LA) ER plus /AR plus breast cancer (BC) in postmenopausal (PM) women
Overmoyer, B., Rugo, H., Schwartzberg, L., Palmieri, C., Taylor, R., Hancock, M., . . . Johnston, M. A. (2016). Phase 2 open label, multinational, randomized, parallel design study investigating the efficacy and safety of GTx-024 on metastatic (MET) or locally advanced (LA) ER plus /AR plus breast cancer (BC) in postmenopausal (PM) women. In CANCER RESEARCH Vol. 76. doi:10.1158/1538-7445.SABCS15-OT2-01-06
SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer
Zwart, W., Flach, K. D., Rudraraju, B., Abdel-Fatah, T. M. A., Gojis, O., Canisius, S., . . . Palmieri, C. (2016). SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer. Clinical Cancer Research, 22(2), 479-491. doi:10.1158/1078-0432.CCR-14-3277
2015
A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition
Zucchini, G., Armstrong, A. C., Wardley, A. M., Wilson, G., Misra, V., Seif, M., . . . Howell, S. J. (2015). A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition. EUROPEAN JOURNAL OF CANCER, 51(18), 2725-2731. doi:10.1016/j.ejca.2015.08.028
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES<SUP>aEuro</SUP>
Speirs, V., Viale, G., Mousa, K., Palmieri, C., Reed, S. N., Nicholas, H., . . . Coombes, R. C. (2015). Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES<SUP>aEuro</SUP>. ANNALS OF ONCOLOGY, 26(9), 1890-1897. doi:10.1093/annonc/mdv242
The Minimum Competences in Non-surgical Oncology that Medical Students Need to Acquire in Order to be Safe Foundation Year 1 (F1) Doctors: A Delphi Survey
Benstead, K., Palmieri, C., Brewster, A., Gilson, D., Jenkins, P., & Booth, J. (2015). The Minimum Competences in Non-surgical Oncology that Medical Students Need to Acquire in Order to be Safe Foundation Year 1 (F1) Doctors: A Delphi Survey. CLINICAL ONCOLOGY, 27(7), 373-379. doi:10.1016/j.clon.2015.03.007
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
Palmieri, C. (2015). Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.. Lancet Oncol..
Effects on outcome of concomitant neoadjuvant chemotherapy-trastuzumab compared with sequential neoadjuvant chemotherapy followed by post-operative trastuzumab
Palmieri, C., Macpherson, I. R. J., Yan, K., Moraes, F. A., Riddle, P., Ahmed, R., . . . Howell, S. J. (2015). Effects on outcome of concomitant neoadjuvant chemotherapy-trastuzumab compared with sequential neoadjuvant chemotherapy followed by post-operative trastuzumab. In CANCER RESEARCH Vol. 75. Retrieved from https://www.webofscience.com/
Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
Saleem, A., Searle, G. E., Kenny, L. M., Huiban, M., Kozlowski, K., Waldman, A. D., . . . Coombes, R. C. (2015). Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer. EJNMMI RESEARCH, 5. doi:10.1186/s13550-015-0103-5
Tumour volume analysis (TVA) as applied to a pilot randomized study of neoadjuvant endocrine versus neoadjuvant chemotherapy (NEOCENT).
Gordon, A., Palmieri, C., Cleator, S. J., Morden, J. P., & Coombes, R. C. (2015). Tumour volume analysis (TVA) as applied to a pilot randomized study of neoadjuvant endocrine versus neoadjuvant chemotherapy (NEOCENT).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. Retrieved from https://www.webofscience.com/
2014
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer
Palmieri, C., Cleator, S., Kilburn, L. S., Kim, S. B., Ahn, S. -H., Beresford, M., . . . Coombes, R. C. (2014). NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 148(3), 581-590. doi:10.1007/s10549-014-3183-4
Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer
Rudraraju, B., Droog, M., Abdel-Fatah, T. M. A., Zwart, W., Giannoudis, A., Malki, M. I., . . . Palmieri, C. (2014). Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 147(2), 295-309. doi:10.1007/s10549-014-3098-0
Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer
Elliott, K. M., Dent, J., Stanczyk, F. Z., Woodley, L., Coombes, R. C., Purohit, A., & Palmieri, C. (2014). Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer. BRITISH JOURNAL OF SURGERY, 101(8), 939-948. doi:10.1002/bjs.9477
Multicenter Experience of Nonpegylated Liposomal Doxorubicin Use in the Management of Metastatic Breast Cancer
Palmieri, C., Misra, V., Januszewski, A., Yosef, H., Ashford, R., Keary, I., & Davidson, N. (2014). Multicenter Experience of Nonpegylated Liposomal Doxorubicin Use in the Management of Metastatic Breast Cancer. Clinical Breast Cancer, 14(2), 85-93. doi:10.1016/j.clbc.2013.10.011
Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund
Ramaswami, R., O'Cathail, S. M., Brindley, J. H., Silcocks, P., Mahmoud, S., & Palmieri, C. (2014). Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund. FUTURE ONCOLOGY, 10(3), 363-376. doi:10.2217/FON.13.210
Prior exposure to chemotherapy: a marker of sensitivity and selection for antiangiogenic therapy in breast cancer?
Xynos, I. D., Tanna, N., Patten, D. K., & Palmieri, C. (2014). Prior exposure to chemotherapy: a marker of sensitivity and selection for antiangiogenic therapy in breast cancer?. EXPERT REVIEW OF ANTICANCER THERAPY, 14(2), 163-172. doi:10.1586/14737140.2014.846220
Breast cancer: Current and future endocrine therapies
Palmieri, C., Patten, D. K., Januszewski, A., Zucchini, G., & Howell, S. J. (2014). Breast cancer: Current and future endocrine therapies. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 382(1), 695-723. doi:10.1016/j.mce.2013.08.001
2013
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.
Eccles, S. A., Aboagye, E. O., Ali, S., Anderson, A. S., Armes, J., Berditchevski, F., . . . Thompson, A. M. (2013). Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.. Breast cancer research : BCR, 15(5), R92. doi:10.1186/bcr3493
Patient attitudes towards undergoing additional breast biopsy for research.
Naim, F., Ballinger, R., Rombach, I., Hadjiminas, D. J., Al-Mufti, R., Hogben, R. K., . . . Cleator, S. J. (2013). Patient attitudes towards undergoing additional breast biopsy for research.. Breast (Edinburgh, Scotland), 22(5), 850-855. doi:10.1016/j.breast.2013.03.011
Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance.
Palmieri, C., Gojis, O., Rudraraju, B., Stamp-Vincent, C., Wilson, D., Langdon, S., . . . Faratian, D. (2013). Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance.. British journal of cancer, 108(10), 2039-2044. doi:10.1038/bjc.2013.199
An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study).
Coombes, R. C., Tat, T., Miller, M. L., Reise, J. A., Mansi, J. L., Hadjiminas, D. J., . . . Stebbing, J. (2013). An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study).. Annals of oncology : official journal of the European Society for Medical Oncology, 24(4), 924-930. doi:10.1093/annonc/mds594
Is the presence of small volume disease in the sentinel node an indication for axillary clearance?
Patten, D. K., Leff, D. R., Wani, Z., Cleator, S. J., Palmieri, C., Coombes, R. C., & Hadjiminas, D. J. (2013). Is the presence of small volume disease in the sentinel node an indication for axillary clearance?. Breast (Edinburgh, Scotland), 22(1), 70-73. doi:10.1016/j.breast.2012.05.006
Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer.
Palmieri, C., Caley, M. P., Purshouse, K., Fonseca, A. -V., Rodriguez-Teja, M., Kogianni, G., . . . Sturge, J. (2013). Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer.. British journal of cancer, 108(1), 163-169. doi:10.1038/bjc.2012.540
ABC of Cancer Care
Palmieri, C., Bird, E., & Simcock, R. (Eds.) (2013). ABC of Cancer Care. Chichester, West Sussex: Wiley-Blackwell.
Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer.
Palmieri, C., Caley, M. P., Purshouse, K., Fonseca, A. V., Rodriguez-Teja, M., Kogianni, G., . . . Sturge, J. (2013). Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer.. Br J Cancer., 108(1), 163-169.
Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor
Mohammed, H., D'Santos, C., Serandour, A. A., Ali, H. R., Brown, G. D., Atkins, A., . . . Carroll, J. S. (2013). Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep, 3, 324-329.
2012
ChIPing away at breast cancer.
Magnani, L., Carroll, J., Zwart, W., & Palmieri, C. (2012). ChIPing away at breast cancer.. The Lancet. Oncology, 13(12), 1185-1187. doi:10.1016/s1470-2045(12)70511-9
A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer.
Palmieri, C., Alifrangis, C., Shipway, D., Tat, T., Watson, V., Mackie, D., . . . Coombes, R. C. (2012). A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer.. The oncologist, 17(11), 1429-1e47. doi:10.1634/theoncologist.2012-0161
Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse.
Palmieri, C., Monteverde, M., Lattanzio, L., Gojis, O., Rudraraju, B., Fortunato, M., . . . Crook, T. (2012). Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse.. British journal of cancer, 107(4), 732-738. doi:10.1038/bjc.2012.308
Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas.
Palmieri, C., Rudraraju, B., Monteverde, M., Lattanzio, L., Gojis, O., Brizio, R., . . . Crook, T. (2012). Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas.. British journal of cancer, 107(2), 375-381. doi:10.1038/bjc.2012.231
NT5E CpG island methylation is a favourable breast cancer biomarker.
Lo Nigro, C., Monteverde, M., Lee, S., Lattanzio, L., Vivenza, D., Comino, A., . . . Crook, T. (2012). NT5E CpG island methylation is a favourable breast cancer biomarker.. British journal of cancer, 107(1), 75-83. doi:10.1038/bjc.2012.212
Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy.
Contractor, K., Challapalli, A., Tomasi, G., Rosso, L., Wasan, H., Stebbing, J., . . . Aboagye, E. (2012). Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy.. Physics in medicine and biology, 57(11), 3419-3433. doi:10.1088/0031-9155/57/11/3419
Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.
Saini, K. S., Taylor, C., Ramirez, A. -J., Palmieri, C., Gunnarsson, U., Schmoll, H. J., . . . de Azambuja, E. (2012). Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.. Annals of oncology : official journal of the European Society for Medical Oncology, 23(4), 853-859. doi:10.1093/annonc/mdr352
TGFβ1-Endo180-dependent collagen deposition is dysregulated at the tumour-stromal interface in bone metastasis.
Caley, M. P., Kogianni, G., Adamarek, A., Gronau, J. H., Rodriguez-Teja, M., Fonseca, A. -V., . . . Sturge, J. (2012). TGFβ1-Endo180-dependent collagen deposition is dysregulated at the tumour-stromal interface in bone metastasis.. The Journal of pathology, 226(5), 775-783. doi:10.1002/path.3958
The 2011 EBCTCG polychemotherapy overview.
Palmieri, C., & Jones, A. (2012). The 2011 EBCTCG polychemotherapy overview.. Lancet (London, England), 379(9814), 390-392. doi:10.1016/s0140-6736(11)61823-0
Genomic analysis of circulating cell-free DNA infers breast cancer dormancy.
Shaw, J. A., Page, K., Blighe, K., Hava, N., Guttery, D., Ward, B., . . . Coombes, R. C. (2012). Genomic analysis of circulating cell-free DNA infers breast cancer dormancy.. Genome research, 22(2), 220-231. doi:10.1101/gr.123497.111
High frequency of complex TP53 mutations in CNS metastases from breast cancer.
Lo Nigro, C., Vivenza, D., Monteverde, M., Lattanzio, L., Gojis, O., Garrone, O., . . . Crook, T. (2012). High frequency of complex TP53 mutations in CNS metastases from breast cancer.. British journal of cancer, 106(2), 397-404. doi:10.1038/bjc.2011.464
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.
Ross-Innes, C. S., Stark, R., Teschendorff, A. E., Holmes, K. A., Ali, H. R., Dunning, M. J., . . . Carroll, J. S. (2012). Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.. Nature, 481(7381), 389-393. doi:10.1038/nature10730
A Randomised Feasibility Study of Docetaxel Versus Vinorelbine in Advanced Breast Cancer
Palmieri, C., Alifrangis, C., Shipway, D., Tat, T., Watson, V., Mackie, D., . . . Coombes, R. C. (2012). A Randomised Feasibility Study of Docetaxel Versus Vinorelbine in Advanced Breast Cancer. The Oncologist, 17(11)(11), 1429-e47.
A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer
Palmieri, C., Alifrangis, C., Shipway, D., Tat, T., Watson, V., Mackie, D., . . . Coombes, R. C. (2012). A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer. Oncologist, 17, 1429-e47..
Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas
Palmieri, C., Rudraraju, B., Monteverde, M., Lattanzio, L., Gojis, O., Brizio, R., . . . Crook, T. (2012). Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas. Br J Cancer., 107, 375-381.
Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse.
Palmieri, C., Monteverde, M., Lattanzio, L., Gojis, O., Rudraraju, B., Fortunato, M., . . . Crook, T. (2012). Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse.. Brit J Cancer, 107(4), 732-738.
2011
Role of fulvestrant in the management of postmenopausal breast cancer.
Krell, J., Januszewski, A., Yan, K., & Palmieri, C. (2011). Role of fulvestrant in the management of postmenopausal breast cancer.. Expert review of anticancer therapy, 11(11), 1641-1652. doi:10.1586/era.11.138
Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.
Stanway, S. J., Palmieri, C., Stanczyk, F. Z., Folkerd, E. J., Dowsett, M., Ward, R., . . . Purohit, A. (2011). Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.. Anticancer research, 31(4), 1367-1372.
Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era.
Palmieri, C., Shah, D., Krell, J., Gojis, O., Hogben, K., Riddle, P., . . . Cleator, S. (2011). Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era.. Clinical breast cancer, 11(2), 93-102. doi:10.1016/j.clbc.2011.03.001
. Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era
Krell, J., James, C. R., Shah, D., Gojis, O., Lim, A., Riddle, P., . . . Palmieri, C. (2011). . Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era. Clin Breast Cancer, 11, 93-102.
Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography
Contractor, K. B., Kenny, L. M., Stebbing, J., Challapalli, A., Al-Nahhas, A., Palmieri, C., . . . Aboagye, E. O. (2011). Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography. Nucl Med Commun, 32, 997-1004.
2010
Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab.
Kenny, L. M., Contractor, K. B., Hinz, R., Stebbing, J., Palmieri, C., Jiang, J., . . . Aboagye, E. O. (2010). Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab.. Clinical cancer research : an official journal of the American Association for Cancer Research, 16(16), 4236-4245. doi:10.1158/1078-0432.ccr-10-0468
The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease.
Gojis, O., Rudraraju, B., Alifrangis, C., Krell, J., Libalova, P., & Palmieri, C. (2010). The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 36(3), 224-229. doi:10.1016/j.ejso.2009.08.002
Surgical oncology: why biopsying metastatic breast cancer should be routine.
Sharma, A., Crook, T., Thompson, A., & Palmieri, C. (2010). Surgical oncology: why biopsying metastatic breast cancer should be routine.. Nature reviews. Clinical oncology, 7(2), 72-74. doi:10.1038/nrclinonc.2009.222
The role of SRC-3 in human breast cancer.
Gojis, O., Rudraraju, B., Gudi, M., Hogben, K., Sousha, S., Coombes, R. C., . . . Palmieri, C. (2010). The role of SRC-3 in human breast cancer.. Nature reviews. Clinical oncology, 7(2), 83-89. doi:10.1038/nrclinonc.2009.219
A review of rechallenging with anthracycline and taxane in the treatment of metastatic breast cancer
Palmieri, C., Krell, J., James, C. R., Harper-Wynne, C., Misra, V., Cleator, S., & Miles, D. (2010). A review of rechallenging with anthracycline and taxane in the treatment of metastatic breast cancer. Nat Rev Clin Oncol. 2010;7:, 7, 561-574.
2009
Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography.
Kenny, L. M., Contractor, K. B., Stebbing, J., Al-Nahhas, A., Palmieri, C., Shousha, S., . . . Aboagye, E. O. (2009). Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography.. Clinical cancer research : an official journal of the American Association for Cancer Research, 15(21), 6649-6657. doi:10.1158/1078-0432.ccr-09-1213
A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.
Cleator, S. J., Ahamed, E., Coombes, R. C., & Palmieri, C. (2009). A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.. Clinical breast cancer, 9 Suppl 1, S6-S17. doi:10.3816/cbc.2009.s.001
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
Barrett-Lee, P. J., Dixon, J. M., Farrell, C., Jones, A., Leonard, R., Murray, N., . . . Verrill, M. W. (2009). Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.. Annals of oncology : official journal of the European Society for Medical Oncology, 20(5), 816-827. doi:10.1093/annonc/mdn728
Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience.
Wang, J., Jain, S., Coombes, C. R., & Palmieri, C. (2009). Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience.. The breast journal, 15(3), 247-253. doi:10.1111/j.1524-4741.2009.00713.x
Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment.
Slade, M. J., Payne, R., Riethdorf, S., Ward, B., Zaidi, S. A. A., Stebbing, J., . . . Coombes, R. C. (2009). Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment.. British journal of cancer, 100(1), 160-166. doi:10.1038/sj.bjc.6604773
R.E. Francis , S.S. Myatt, J .Krol, J. Hartman, B. Peck, U.B. McGovern, J. Wang, S.K. Guest, A. Filipovic, O. Gojis, C. Palmieri, D. Peston, S. Shousha, Q. Yu, P. Sicinski, R.C. Coombes, E.W. Lam . FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer
Francis, R. E., Myatt, S. S., Krol, J., Hartman, J., Peck, B., McGovern, U. B., . . . Lam, E. W. (2009). R.E. Francis , S.S. Myatt, J .Krol, J. Hartman, B. Peck, U.B. McGovern, J. Wang, S.K. Guest, A. Filipovic, O. Gojis, C. Palmieri, D. Peston, S. Shousha, Q. Yu, P. Sicinski, R.C. Coombes, E.W. Lam . FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol., 35, 57-68.
[11C]choline Positron Emission Tomography (PET) in Breast Cancer.
positron emission tomography in estrogen receptor-positive breas, C. C. (2009). [11C]choline Positron Emission Tomography (PET) in Breast Cancer.. Clin Cancer Res., 15, 5503-5510.
2008
Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer.
Stavridi, F., & Palmieri, C. (2008). Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer.. Expert review of anticancer therapy, 8(12), 1859-1869. doi:10.1586/14737140.8.12.1859
Ethnicity and breast cancer research.
Palmieri, C., Coombes, R. C., Kim, S. -B., & Cleator, S. (2008). Ethnicity and breast cancer research.. Lancet (London, England), 372(9634), 188-189. doi:10.1016/s0140-6736(08)61052-1
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.
Kenny, L. M., Coombes, R. C., Oulie, I., Contractor, K. B., Miller, M., Spinks, T. J., . . . Aboagye, E. O. (2008). Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 49(6), 879-886. doi:10.2967/jnumed.107.049452
Adjuvant radiotherapy for breast cancer
Hiley, C., Tutt, A., Torres, M., & Palmieri, C. (2008). Adjuvant radiotherapy for breast cancer. BMJ, 337, a2843.
Adjuvant radiotherapy for breast cancer.
Hiley, C., Tutt, A., Torres, M., & Palmieri, C. (2008). Adjuvant radiotherapy for breast cancer.. BMJ, 337, a2843.
R.Thomas & C.Palmieri. Angiosarcoma of the breast following breast preserving surgery and radiotherapy: a review of the literature.
Thomas, R., & Palmieri, C. (2008). R.Thomas & C.Palmieri. Angiosarcoma of the breast following breast preserving surgery and radiotherapy: a review of the literature.. Nat Clin Pract Oncol., (5), 727-736.
2007
C.Palmieri, T.Dhillon, R.A.Fisher, A.M.Young, D.Short, H.Mitchell, P.Savage, E.S. Newlands, B.W. Hancock , M.J.Seckl. Management and outcome of healthy women with a persistently elevated β-hCG
Palmieri, C., Dhillon, T., Fisher, R. A., Young, A. M., Short, D., Mitchell, H., . . . Seckl, M. J. (2007). C.Palmieri, T.Dhillon, R.A.Fisher, A.M.Young, D.Short, H.Mitchell, P.Savage, E.S. Newlands, B.W. Hancock , M.J.Seckl. Management and outcome of healthy women with a persistently elevated β-hCG. Gynecol Oncol, 106, 35-43.
Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.
Heller, W., Mazhar, D., Ward, R., Sinnett, H. D., Lowdell, C., Phillips, R., . . . Coombes, R. C. (2007). Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.. Oncology reports, 17(1), 253-259. doi:10.3892/or.17.1.253
2006
AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy.
Palmieri, C., Treibel, T., Large, O., & Bower, M. (2006). AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy.. QJM : monthly journal of the Association of Physicians, 99(12), 811-826. doi:10.1093/qjmed/hcl115
Serum 25-hydroxyvitamin D levels in early and advanced breast cancer.
Palmieri, C., MacGregor, T., Girgis, S., & Vigushin, D. (2006). Serum 25-hydroxyvitamin D levels in early and advanced breast cancer.. Journal of clinical pathology, 59(12), 1334-1336. doi:10.1136/jcp.2006.042747
Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia.
Dhillon, T., Palmieri, C., Sebire, N. J., Lindsay, I., Newlands, E. S., Schmid, P., . . . Seckl, M. J. (2006). Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia.. The Journal of reproductive medicine, 51(11), 879-887.
AIDS associated malignancies
Bower, M., Palmieri, C., & Stebbing, J. (2006). AIDS associated malignancies. Update on Cancer Therapeutics, 1(2), 221-234. doi:10.1016/j.uct.2006.04.010
The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma.
Stebbing, J., Mazhar, D., Lewis, R., Palmieri, C., Hatzimichael, E., Nelson, M., . . . Bower, M. (2006). The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma.. Annals of oncology : official journal of the European Society for Medical Oncology, 17(3), 503-506. doi:10.1093/annonc/mdj091
AIDS related malignancies: changing epidemiology and impact of HAART.
Bower, M., Palmieri, C., & Dhillon, T. (2006). AIDS related malignancies: changing epidemiology and impact of HAART.. Current Opin Inf Dis, 19, 14-19.
Pulmonary AIDS related Kaposi Sarcoma in era of HAART.
Palmieri, C., Dhillon, T., Thirlwell, C., Newsom-Davis, T., Young, A. M., Nelson, M., . . . Bower, M. (2006). Pulmonary AIDS related Kaposi Sarcoma in era of HAART.. HIV Medicine, 7, 291-293.
2005
Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis.
Fraser, S. P., Diss, J. K. J., Chioni, A. -M., Mycielska, M. E., Pan, H., Yamaci, R. F., . . . Djamgoz, M. B. A. (2005). Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis.. Clinical cancer research : an official journal of the American Association for Cancer Research, 11(15), 5381-5389. doi:10.1158/1078-0432.ccr-05-0327
Therapeutic monoclonal antibodies in oncology.
Levene, A. P., Singh, G., & Palmieri, C. (2005). Therapeutic monoclonal antibodies in oncology.. Journal of the Royal Society of Medicine, 98(4), 146-152. doi:10.1177/014107680509800403
Targeted histone deacetylase inhibition for cancer prevention and therapy.
Palmieri, C., Coombes, R. C., & Vigushin, D. M. (2005). Targeted histone deacetylase inhibition for cancer prevention and therapy.. Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques, 63, 147-181. doi:10.1007/3-7643-7414-4_7
2004
The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts.
Palmieri, C., Saji, S., Sakaguchi, H., Cheng, G., Sunters, A., O'Hare, M. J., . . . Lam, E. W. -F. (2004). The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts.. Journal of molecular endocrinology, 33(1), 35-50. doi:10.1677/jme.0.0330035
Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial.
Neary, N. M., Small, C. J., Wren, A. M., Lee, J. L., Druce, M. R., Palmieri, C., . . . Bloom, S. R. (2004). Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial.. The Journal of clinical endocrinology and metabolism, 89(6), 2832-2836. doi:10.1210/jc.2003-031768
The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival.
Palmieri, C., Lam, E. W. -F., Mansi, J., MacDonald, C., Shousha, S., Madden, P., . . . Coombes, R. C. (2004). The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival.. Clinical cancer research : an official journal of the American Association for Cancer Research, 10(7), 2421-2428. doi:10.1158/1078-0432.ccr-03-0215
2003
Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1beta-induced paracrine growth factor for human breast cells.
Palmieri, C., Roberts-Clark, D., Assadi-Sabet, A., Coope, R. C., O'Hare, M., Sunters, A., . . . Coombes, R. C. (2003). Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1beta-induced paracrine growth factor for human breast cells.. The Journal of endocrinology, 177(1), 65-81. doi:10.1677/joe.0.1770065
2002
Estrogen receptor beta in breast cancer.
Palmieri, C., Cheng, G. J., Saji, S., Zelada-Hedman, M., Wärri, A., Weihua, Z., . . . Gustafsson, J. -A. (2002). Estrogen receptor beta in breast cancer.. Endocrine-related cancer, 9(1), 1-13. doi:10.1677/erc.0.0090001
2001
Estrogen receptors and proliferation markers in primary and recurrent breast cancer.
Jensen, E. V., Cheng, G., Palmieri, C., Saji, S., Mäkelä, S., Van Noorden, S., . . . Gustafsson, J. A. (2001). Estrogen receptors and proliferation markers in primary and recurrent breast cancer.. Proceedings of the National Academy of Sciences of the United States of America, 98(26), 15197-15202. doi:10.1073/pnas.211556298
2000
Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer.
Udom, D. I., Vigushin, D. M., Linardou, H., Graham, H., Palmieri, C., & Coombes, R. C. (2000). Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer.. European journal of cancer (Oxford, England : 1990), 36(2), 177-182. doi:10.1016/s0959-8049(99)00219-1